← Leaderboards
Henry I Robins
University Of Wisconsin Madison
$703,981
Attributed
$703,981
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$703,981 · 4
By mechanism
M01$703,981 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Joan H Schiller$7,395,575
- Shigeki Miyamoto$12,775,702
- Howard H Bailey$27,057,671
- Mandi J. Lopez$2,490,118
- George Wilding$32,976,854
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyHuman Therapy EvaluationHuman SubjectClinical ResearchCombination Cancer TherapyNeoplasm /Cancer ThermotherapySarcomaEtoposideCarboplatinCombination ChemotherapyIfosfamideGliomaAntineoplasticsDrug Screening /EvaluationDrug Administration Rate /DurationMelphalanMelanomaNeoplasm /Cancer Relapse /RecurrenceHyperthermia TherapyPerfusionPhenylacetatesUnited States National Institutes Of HealthAdverse EffectsVorinostat
Grant awards (14)
PHASE I STUDY OF VORINOSTAT IN COMBINATION WITH TEMOZOLOMIDE IN MALIGNANT GLIOMA$106
M01 · FY2007 · RR · contact PI
PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GLIOMA$106,600
M01 · FY2002 · RR
PHASE II EVALUATION OF IV MELPHALAN (L PAM) AND WBH FOR MALIGNANT MELANOMA$106,600
M01 · FY2002 · RR
PHASE II WBH AND IFOSFAMIDE/CARBOPLATIN/ETOPOSIDE THERAPY IN SARCOMA$106,600
M01 · FY2002 · RR
PHASE II EVALUATION OF IV MELPHALAN (L PAM) AND WBH FOR MALIGNANT MELANOMA$106,600
M01 · FY2001 · RR
PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GLIOMA$106,600
M01 · FY2001 · RR
PHASE II WBH AND IFOSFAMIDE/CARBOPLATIN/ETOPOSIDE THERAPY IN SARCOMA$106,600
M01 · FY2001 · RR
PHASE II WBH AND IFOSFAMIDE/CARBOPLATIN/ETOPOSIDE THERAPY IN SARCOMA$12,855
M01 · FY2001 · RR
PHASE II EVALUATION OF IV MELPHALAN (L PAM) AND WBH FOR MALIGNANT MELANOMA$12,855
M01 · FY2001 · RR
PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GLIOMA$12,855
M01 · FY2001 · RR
PHASE II EVALUATION OF IV MELPHALAN (L PAM) AND WBH FOR MALIGNANT MELANOMA$12,855
M01 · FY2000 · RR
PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GLIOMA$12,855
M01 · FY2000 · RR
PHASE II WBH AND IFOSFAMIDE/CARBOPLATIN/ETOPOSIDE THERAPY IN SARCOMA$0
M01 · FY2000 · RR
PHASE II WBH AND IFOSFAMIDE/CARBOPLATIN/ETOPOSIDE THERAPY IN SARCOMA$0
M01 · FY2000 · RR